New LC–MS workflows for infectious disease diagnosis: Thermo Fisher announce collaboration
Biotechnology product manufacturer, Thermo Fisher Scientific (MD, USA) have announced its’ entry into a new collaboration with diagnostic platform designer NanoPin Technologies (AZ, USA). The new collaboration seeks to develop novel LC–MS workflows to improve the available detection technology for blood-based infectious diseases. The collaboration aims to enhance the information available to healthcare providers and thus improve patient care.
The collaboration will see the NanoPin diagnostic platform, manufactured by NanoPin Technologies, combined with Thermo Fisher Scientific’s LC–MS technology. The diagnostic platform – which has been used to provide rapid quantitative results from patient blood samples – will detect disease-related antigens direct from patient blood samples using Thermo Fisher Scientific’s LC–MS technology.
Through the combination of the two companies’ technology, the collaborations’ aims are to develop a range of sensitive clinical assays for infectious diseases. The development of novel, rapid and robust assays could reduce the time taken for healthcare providers to get critical information. Decreasing the time taken for healthcare providers to glean information regarding the stage of infection the patient is at, as well as the patient response to the prescribed treatment, could significantly improve infectious disease treatment and control across the globe.
Senior Director of clinical research, chromatography and mass spectrometry (Thermo Fisher Scientific) explained: “Time is critical when it comes to the diagnosis and treatment of patients suffering from infectious disease, and current methods do not facilitate prompt diagnosis and rapid evaluation of treatment response.”
Thomas Tombler, CEO (NanoPin Technologies) added: “The current diagnostic solutions available for the detection and monitoring of infectious disease are not sufficient because they limit patient outcomes and the global management of such ailments. Through our agreement with Thermo Fisher, our unique diagnostic platform has the potential to change how infectious diseases, such as tuberculosis, are detected, treated and controlled by solving the unmet needs of healthcare providers managing patient care throughout the world.”
